Your browser doesn't support javascript.
loading
Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance.
Alferiev, Ivan S; Guerrero, David T; Guan, Peng; Nguyen, Ferro; Kolla, Venkatadri; Soberman, Danielle; Pressly, Benjamin B; Fishbein, Ilia; Brodeur, Garrett M; Chorny, Michael.
Afiliación
  • Alferiev IS; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Guerrero DT; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Guan P; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Nguyen F; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Kolla V; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Soberman D; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Pressly BB; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Fishbein I; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Brodeur GM; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Chorny M; Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
FASEB J ; 36(3): e22213, 2022 03.
Article en En | MEDLINE | ID: mdl-35192728
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Profármacos / Resistencia a Antineoplásicos / Inhibidores de Topoisomerasa I / Neuroblastoma / Antineoplásicos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: FASEB J Asunto de la revista: BIOLOGIA / FISIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Profármacos / Resistencia a Antineoplásicos / Inhibidores de Topoisomerasa I / Neuroblastoma / Antineoplásicos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: FASEB J Asunto de la revista: BIOLOGIA / FISIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos